The document discusses biostimology, a technology aimed at reducing abdominal obesity and metabolic syndrome through non-destructive muscular stimulation. It highlights the effectiveness of this treatment in improving metabolic markers and reducing visceral fat without invasive procedures. Biostimology is clinically proven to benefit various health issues, including diabetes and fatty liver disease, with specific protocols for different obesity classes.

1. Biostimology - Naturally effective

2. Content
I. The Technology
II. The results: medical & aesthetic
III. The diagnostic
IV. The device
V. The medical studies

3. Introduction

4. Biostimology treatment
Cryo, laser, or IR… treatments
The Next Generation In
Body Contouring

5. • Abdominal obesity:
Waist circumference (variable depending
to ethnicity and region)
USA: > 88 cm (F) or > 102 cm (M)
• Plus
-Elevated TG
-Lowered HDL-cholesterol < 40 (M) or < 50 (F)
mg/dl
-Elevated arterial pressure > 130/85 mm Hg
-Accumulated fasting glycemia > 100 mg/dl
Abdominal obesity + 2 other risk factors
Metabolic syndrome

6. Hypertriglyceridemia
>1.5 g/l
Low HDL cholesterol
< 0.4 g/l
No abdominal
obesity
Abdominal
obesity
No abdominal
obesity
Abdominal
obesity
Men Women Men Women
Abdominal obesity > 102 in men > 88 cm in women NCEP JAMA 2001
Prevalence of Hypertriglyceridemia and low
HDL in patients with abdominal obesity
ORNICAR study: Transversal study in France with 3391 patients in 2006

7. Arterial hypertension
> 140-90 mm Hg
Type 2 diabetes
Glycemia ≥ 1.26 g/I
No abdominal
obesity
Abdominal
obesity
No abdominal
obesity
Abdominal
obesity
Men Women Men Women
ORNICAR study: Transversal study in France with 3391 patients in 2006
Abdominal obesity > 102 in men > 88 cm in women NCEP JAMA 2001
Prevalence of Arterial Hypertension and
type 2 Diabetes in patients with abdominal
obesity

8. A tool for identifying the individuals candidates for Redustim
Hypertriglyceridemic waist
Source: International Chair on cardio metabolic Risk www.myhealthywaist.org
NORMAL ADIPOSE TISSUE (FUNCTIONAL) NORMAL ADIPOSE TISSUE (FUNCTIONAL)
OBESITY PHENOTYPE CLINICAL SCREENING OBESITY PHENOTYPE CLINICAL SCREENING
Subcutaneous obesity Elevated waist circumference
• Favourable genotype
• Better diet
• Physically active
• Sensitive to insulin
Waist size
Normal
triglycerides
• Favourable genotype
• Better diet
• Physically active
• Sensitive to insulin
Waist size
Intra-abdominal obesity Hypertriglyceridemic waist
Elevated
triglycerides
CORRELATIONS WITH THE HYPERTRIGLYCERIDEMIC WAIST
Atherogenic metabolic triad
Cholesterol / HDL cholesterol
Postprandial hyperlipidemia
Glucose intolerance
Hyperinsulinemia
Blood pressure
Cardiovascular risk
Risk of CVD
Aortic calcification rate
Risk of type 2 diabetes
®Professeur Djamel-Eddine Nibouche

9. Elevated waist
circumference
>>> BMI
subcutaneous
Visceral
Front Visceral adipose tissue
BACK Subcutaneous adipose tissue
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice European Journal of
Cardiovascular Prevention and Rehabilitation 2003; 10 : Sl-S78
Visceral obesity
…better marker of the cardio metabolic risk than the BMI

10. The Biostimology®

11. Biostimology vs. Energy delivery technologies
The various existing technologies
have a destructive effect at the
cellular and tissue level.
The interest of Biostimology whose
mechanism of action is based on
the muscular stimulation without
any destructive cellular process.
Biostimology doesn't targert fat
cell but muscle cell!
vs

12. The muscle cells targeted

13. Magnetic field will create a depolarisation on the membrane of smooth and
striated muscle cells

14. • The presence of calcium in
your muscles enables
movement.
• Muscle contraction begins
with an electrical "go"
signal from your brain. The
signal stimulates the SR to
open its calcium gates,
flooding the myofilaments
with calcium. The
simultaneous shortening of
thousands of microscopic
myofilaments leads to
muscle contraction.
Role of Ionic Calcium (Ca2+) in the contraction mechanism

15. Sarcoplasmic reticulum
Myosin
Actin
In obese population, we found inflammation at the sarcoplasmic
reticulum, It means that Ca2+ transfer isn't happening properly.
The cause
(1)Stéatose hépatique et stress du réticulum endoplasmique
http://www.ipubli.inserm.fr/bitstream/handle/10608/7731/MS_2012_01_13.html?sequence=10
(2)Inflammation and endoplasmic reticulum stress in obesity and diabetes
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885768/

16. Frequency 50 Hz
… can increase the activity of the ATPases Ca++
from 5 to 10 %(1)(2) at the sarcoplasmic reticulum.
Sarcoplasmic reticulum
+
-
How the Biostimology® procedure works
(1) in 1995, M.Blank, L. Soo, V.Papstein of the department of Physiology and Cellular Biophysics, (Columbia
University - the USA) demonstrated that a comparable magnetic field of frequency between 0 and 70 Hz
and varying 0 - 2 gauss allowed to increase the activity of the ATPases Ca++ from at 10 %, that is a level
of stimulation comparable to the calcic ATPases.
(2) 2009 : PREDICTIVE STUDY ON “DNA CHIPS”
The increase in calcium and in ATP, as well as the activation of these receptors, have been described
during the use of devices generating electromagnetic energy pulses.

17. which triggers the release of calcium ions from the sarcoplasmic
reticulum.

19. The main mechanism uses lipolysis which hydrolyses reserve
triglycerides and release ATP from visceral and subcutaneous fat.

20. The results

21. Improvement of the metabolic markers and risk factors during
Biostimology® treatment in the obese subject.
Unique !
Medical results

22. SCANNER IMAGING STUDY OF VISCERAL FAT
Dr Bernadette Carpentier, Dr Habib Nouira (Medical scan clinic -
Nouira)
• Waist size ≥ 90 cm
• Triglycerides ≥ 1.69 mmo/L and/or
• HDL Cholesterol <1.03 mmol/l)
In a 4-week observational trial with REDUSTIM, 3 sessions a week were
administered on 20 patients, comparing patient parameters before and after
the study.
Reduction of the visceral adiposity
by Redustim

23. Before (S0)
After (S12)
Visceral fat

24. Visceral fat reduction

25. Blood pressure reduction

26. Fatty liver reduction (ASAT)

27. After invasive lipolysis treatments, the liver is one of the main organs responsible for
metabolizing the damaged fat cells.
You livers needs to detox*.
The Biostimology reduces the liver transaminase:
ALT: a 23% reduction, AST: a 13% reduction.
High AST and ALT are an indicator of liver damage.
*DR Cory Torgerson, MD, PhD, FRCSC Toronto Plastic Surgeon

28. Arms: -1,8 cm
Waist: -6,5 cm
Hips: -7,2 cm
Thighs: -3,9 cm
Knees: -2,7 cm
Calves: -1,8 cm
Aesthetic results

29. The diagnostic

30. Positive energy balance
Elevated capacity for fat storage
at the subcutaneous level
Weak capacity for fat storage at
the subcutaneous level
No ectopic fat Presence of ectopic fat
HeartLiver Muscle Hepatic
steatosis
Epicardial
fat
Muscular
triglycerides
Biostimology® candidates
Biostimology® candidates are patients with:
1/Large waistline
2/Elevated triglycerides
3/Low HDL

31. The device

33. Medical indications are:
Obesity class 2 35< BMI <40
24 x 45 min sessions (3 sessions a week).
Obesity class 1 30< BMI <35
18 x 45 min sessions (3 sessions a week).
Obesity
Overweight 25< BMI <30
12x 45 min sessions (3 sessions a week).
Obesity treatment

34. Medical indications are:
• Treatment of abdominal
obesity in menopausal
women
• PCOS in overweight and
obese women
• IVF Protocol
Gynecology

35. Obesity class 2 101< CM<115
24 x 45 min sessions (3 sessions a week).
Obesity class 1 91< CM<100
18 x 45 min sessions (3 sessions a week).
Overweight 85< CM<90
12 x 45 min sessions (3 sessions a week).
Obesity class 3 120< CM
36 x 45 min sessions (2 sessions a week).
The protocol

36. The studies

37. Clinical studies
• Electromagnetic fields applied to the reduction of abdominal obesity.
1. PMID: 22171794 DOI: 10.3109/14764172.2011.649763
https://www.ncbi.nlm.nih.gov/pubmed/22171794
2. Journal of Cosmetic and Laser Therapy, 2011
3. Integrative Obesity and Diabetes, 2018
• Predictive study on “DNA Chips” - 2009
• Clinical study on ReduStim
• Double-blind randomized
• clinical study – 2010
• Functional study on fertility – 2011
• Scanner imaging study of visceral fat
• Clinical study on ReduStim SP
• New studies (in progress)
• METABOLSTIM: Evaluation of the potential effects of ReduStim treatment
in patients with metabolic syndrome.
• FertiStim2: Evaluation of fertility parameters in overweight and
obese infertile patients after a reduction in their waist circumference.

38. The interest of Biostimology® whose mechanism of action is based
on the muscular stimulation without any destructive cellular process.
The Biostimology®
• The unique protocol that can treat the visceral fat
• Clinically proven
• Lasting results
• Painless and non-invasive
• No special diets
• No alternatives
• Medical claims: diabetes, fatty liver, stroke …

39. Thank you!